CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021
August 04 2021 - 4:05PM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, announced today that the
company will release its second quarter 2021 financial results
after the market closes on Tuesday, August 10, 2021. Management
will host a conference call with a slide presentation at 5:00 p.m.
ET (2:00 p.m. PT) on the same day to provide an update on the
company’s business.
Details for the Conference Call and Slide
Presentation: Date: August 10, 2021Time: 5:00 p.m. ET
(2:00 p.m. PT)
Conference Audio
- Dial-in U.S. and Canada: (877) 300-8521
- Dial-in International: (412) 317-6026
- Conference ID No.: 10159293
Slide Presentation
- Please visit
https://us02web.zoom.us/j/84796437737?pwd=R2t0eEFRVDVlVDVZMTdhT0pGWVVsUT09
and enter password CWBR, or
- Go to www.cohbar.com and click on
CohBar Q2 2021 Investor Presentation at the top of homepage.
For individuals participating in the Investor Call and Slide
Presentation, please call into the conference audio and log into
Zoom approximately 10 minutes prior to its start. Please note, no
audio will be available through Zoom.
An audio replay of the call will be available beginning at 8:00
p.m. Eastern Time on August 10, 2021, through 11:59 p.m. Eastern
Time on August 31, 2021. To access the recording please dial (844)
512-2921 in the U.S. and Canada, or (412) 317-6671 internationally,
and reference Conference ID# 10159293. The audio recording along
with the slide presentation will also be available at
www.cohbar.com during the same period.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the potential to
regulate key processes in multiple systems and organs in the body.
To date, the company has discovered more than 100 mitochondrial
derived peptides and generated over 1,000 analogs. CohBar’s efforts
focus on the development of these peptides into therapeutics that
offer the potential to address a broad range of diseases associated
with the underlying impact of mitochondrial dysfunction. The
company’s lead compound, CB4211, recently completed a Phase 1a/1b
clinical trial for NASH and obesity. In addition, CohBar has four
preclinical programs, with the most advanced being CB5138-3 for
idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases,
which is currently in IND-enabling studies. The preclinical
programs also include the CB5064 Analogs for acute respiratory
distress syndrome (ARDS) including COVID-19 associated ARDS, CB5046
Analogs for CXCR4-related cancer and orphan diseases, and MBT3
Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024